FASEB SRC: The Ubiquitin & Ub-like proteins Conference: Cell Functions and Therapeutic Targeting

FASEB SRC:泛素

基本信息

项目摘要

Summary/Abstract The 2022 FASEB Summer Research Conference on Ubiquitin & Ub-like proteins: Cell Functions and Therapeutic Targeting will be held at the Southbridge Hotel and Conference Center, Southbridge, Massachusetts, July 24th to July 28th, 2022. This FASEB-sponsored conference has been held biannually since 1989; this application seeks support for the 2022 conference, which was delayed due to COVID-19 from 2020. The conference will bring together approximately 150 investigators (junior and senior scientists, postdoctoral fellows, graduate students, and people from industry and government) for discussions of recent advances in the areas of regulated proteolysis and signaling by ubiquitin (UB) and ubiquitin-like (UBL) protein modification, with special emphasis on human diseases. Protein ubiquitination cuts across all fields of biology and the diversity of its impacts cannot be overstated. The selective degradation of proteins by the ubiquitin system is a mechanism for control of virtually all aspects of eukaryotic cell biology, including the cell cycle, transcription, metabolic pathways, development, and antigen processing. In addition, non-proteolytic functions of ubiquitination and UBL modification in protein trafficking and signaling are critical for processes that involve membrane receptors and signaling in the innate immune system, while others help to coordinate the DNA damage response. Dysfunction of the system is involved in many disease processes, particularly cancer, neurologic and developmental diseases, and viral and microbial infectious diseases. In addition, UB and UBL proteins are critical in infectious diseases, and it is now evident that microbes encode UBL proteins, that bacteria and viruses produce enzymes to modulate and/or emulate cellular ubiquitination pathways in host cells, and that cells defend themselves against infectious agents with specific UBL proteins. The topics of eight scientific sessions will be: (i) Mechanism of Ubiquitin Conjugation & Deconjugation; (ii) Molecular Machines; (iii) Disease Pathology; (iv) Ub-like Proteins and Atypical Ubiquitin; (v) Protein Quality Control and Stress; (vi) Organelles and Pathways; (vii) Therapeutic Targeting; (viii) Signaling Pathways and Cell Fate. In addition, there will be two poster sessions and a Meet the Experts discussion panel focused on career development. This conference will be a timely and important meeting in this rapidly growing research area. It is unique in that it provides a format that brings together an extraordinary range of investigators whose collective approaches encompass cell biological, biochemical, structural biology, molecular and genetic methods that address central issues in the regulation of cellular proliferation and signaling pathways. The FASEB SRC format provides a safe and inclusive environment that encourages informal and open discussions among the participants and this in turn fosters initiation of collaborative efforts and stimulates future research directions to broaden the understanding of the roles of UB, the proteasome, and UBL proteins in health and disease.
摘要/摘要 2022 年 FASEB 夏季研究会议泛素和泛素样蛋白:细胞功能和 靶向治疗将在 Southbridge 酒店和会议中心举行, 马萨诸塞州,2022 年 7 月 24 日至 7 月 28 日。该 FASEB 主办的会议每两年举行一次 自 1989 年以来;此应用程序寻求对 2022 年会议的支持,该会议由于 COVID-19 而被推迟 2020 年。会议将汇集约 150 名研究人员(初级和高级科学家、 博士后研究员、研究生以及来自工业界和政府的人士)讨论最近的研究 泛素(UB)和泛素样(UBL)蛋白调节蛋白水解和信号传导领域的进展 修改,特别强调人类疾病。蛋白质泛素化跨越生物学的所有领域 其影响的多样性怎么强调也不为过。泛素选择性降解蛋白质 系统是控制真核细胞生物学几乎所有方面的机制,包括细胞周期, 转录、代谢途径、发育和抗原加工。此外,非蛋白水解功能 蛋白质运输和信号传导中的泛素化和 UBL 修饰对于涉及的过程至关重要 先天免疫系统中的膜受体和信号传导,而其他则有助于协调 DNA 损害反应。该系统的功能障碍涉及许多疾病过程,特别是癌症, 神经系统和发育疾病,以及病毒和微生物感染性疾病。此外,UB 和 UBL 蛋白质在传染病中至关重要,现在很明显微生物编码 UBL 蛋白质, 细菌和病毒产生酶来调节和/或模拟宿主细胞泛素化途径 细胞,并且细胞利用特定的 UBL 蛋白来防御感染因子。八个主题 科学会议将包括: (i) 泛素缀合和解缀合机制; (ii) 分子机器; (iii) 疾病病理学; (iv) 泛素样蛋白和非典型泛素; (v) 蛋白质质量控​​制和应激; (六) 细胞器和途径; (vii) 治疗目标; (viii)信号传导途径和细胞命运。此外, 将举行两次海报会议和一次与专家会面的讨论小组,重点关注职业发展。 这次会议对于这个快速发展的研究领域来说将是一次及时而重要的会议。它的独特之处在于 它提供了一种形式,将范围广泛的调查人员聚集在一起,他们的集体方法 涵盖细胞生物学、生物化学、结构生物学、分子和遗传学方法,解决核心问题 细胞增殖和信号传导途径的调节问题。 FASEB SRC 格式提供了 安全和包容的环境,鼓励参与者之间进行非正式和公开的讨论,并且 反过来,促进合作努力的启动,并刺激未来的研究方向,以拓宽研究范围 了解 UB、蛋白酶体和 UBL 蛋白在健康和疾病中的作用。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

CLAUDIO A.P. JOAZEIRO其他文献

CLAUDIO A.P. JOAZEIRO的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('CLAUDIO A.P. JOAZEIRO', 18)}}的其他基金

A New E3 Ligase Implicated in Protein Quality Control and Neurodegeneration
一种与蛋白质质量控​​制和神经变性有关的新 E3 连接酶
  • 批准号:
    8292845
  • 财政年份:
    2012
  • 资助金额:
    $ 1.3万
  • 项目类别:
A New E3 Ligase Implicated in Protein Quality Control and Neurodegeneration
一种与蛋白质质量控​​制和神经变性有关的新 E3 连接酶
  • 批准号:
    8410088
  • 财政年份:
    2012
  • 资助金额:
    $ 1.3万
  • 项目类别:
A New E3 Ligase Implicated in Protein Quality Control and Neurodegeneration
一种与蛋白质质量控​​制和神经变性有关的新 E3 连接酶
  • 批准号:
    8590232
  • 财政年份:
    2012
  • 资助金额:
    $ 1.3万
  • 项目类别:
Small Molecule Inhibitors of Mdm2 E3 Ubiquitin Ligase Activity for Cancer Therapy
Mdm2 E3 泛素连接酶活性的小分子抑制剂用于癌症治疗
  • 批准号:
    9055550
  • 财政年份:
    2012
  • 资助金额:
    $ 1.3万
  • 项目类别:
Small Molecule Inhibitors of Mdm2 E3 Ubiquitin Ligase Activity for Cancer Therapy
Mdm2 E3 泛素连接酶活性的小分子抑制剂用于癌症治疗
  • 批准号:
    8434835
  • 财政年份:
    2012
  • 资助金额:
    $ 1.3万
  • 项目类别:
Small Molecule Inhibitors of Mdm2 E3 Ubiquitin Ligase Activity for Cancer Therapy
Mdm2 E3 泛素连接酶活性的小分子抑制剂用于癌症治疗
  • 批准号:
    8616725
  • 财政年份:
    2012
  • 资助金额:
    $ 1.3万
  • 项目类别:
Small Molecule Inhibitors of Mdm2 E3 Ubiquitin Ligase Activity for Cancer Therapy
Mdm2 E3 泛素连接酶活性的小分子抑制剂用于癌症治疗
  • 批准号:
    8815096
  • 财政年份:
    2012
  • 资助金额:
    $ 1.3万
  • 项目类别:
Small Molecule Inhibitors of Mdm2 E3 Ubiquitin Ligase Activity for Cancer Therapy
Mdm2 E3 泛素连接酶活性的小分子抑制剂用于癌症治疗
  • 批准号:
    9055550
  • 财政年份:
    2012
  • 资助金额:
    $ 1.3万
  • 项目类别:
Small Molecule Inhibitors of Mdm2 E3 Ubiquitin Ligase Activity for Cancer Therapy
Mdm2 E3 泛素连接酶活性的小分子抑制剂用于癌症治疗
  • 批准号:
    8238648
  • 财政年份:
    2012
  • 资助金额:
    $ 1.3万
  • 项目类别:
A New E3 Ligase Implicated in Protein Quality Control and Neurodegeneration
一种与蛋白质质量控​​制和神经变性有关的新 E3 连接酶
  • 批准号:
    8787516
  • 财政年份:
    2012
  • 资助金额:
    $ 1.3万
  • 项目类别:

相似海外基金

Core E: Biosample Core
核心 E:生物样本核心
  • 批准号:
    10555694
  • 财政年份:
    2023
  • 资助金额:
    $ 1.3万
  • 项目类别:
Using a Health Disparity Research Framework to examine mechanisms linking Obstructive Sleep Apnea with higher Alzheimer’s disease risk in older Blacks/African-Americans
使用健康差异研究框架来研究老年黑人/非裔美国人中阻塞性睡眠呼吸暂停与阿尔茨海默病较高风险之间的联系机制
  • 批准号:
    10662903
  • 财政年份:
    2023
  • 资助金额:
    $ 1.3万
  • 项目类别:
Deep learning for prediction of Mild Cognitive Impairment and Dementia of the Alzheimer's type
深度学习预测轻度认知障碍和阿尔茨海默氏症型痴呆
  • 批准号:
    10662094
  • 财政年份:
    2023
  • 资助金额:
    $ 1.3万
  • 项目类别:
Using a Health Disparity Research Framework to examine mechanisms linking Obstructive Sleep Apnea with higher Alzheimer’s disease risk in older Blacks/African-Americans
使用健康差异研究框架来研究老年黑人/非裔美国人中阻塞性睡眠呼吸暂停与阿尔茨海默病较高风险之间的联系机制
  • 批准号:
    10662903
  • 财政年份:
    2023
  • 资助金额:
    $ 1.3万
  • 项目类别:
Water Emergency Team (WET): Community-Driven Rapid Response Team to Evaluate Antibiotic-Resistant Bacteria Exposures and Household Environmental Health Risks from Sewer Overflows and Basement Flooding
水应急小组 (WET):社区驱动的快速响应小组,评估下水道溢出和地下室洪水导致的抗生素耐药细菌暴露和家庭环境健康风险
  • 批准号:
    10686675
  • 财政年份:
    2023
  • 资助金额:
    $ 1.3万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了